Filgotinib Maleate

Tier C — Watch / trade

Filgotinib Maleate

Galapagos Nv

Originator

2020

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：JAK1

Brand：Jyseleca

Indications (approved)：Ulcerative colitis, Rheumatoid arthritis

Regional status

Phase III

2016-07-27

Approved

2020-09-24

China

Japan

Approved

2020-09-25

Factories producing this API1

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

1 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Filgotinib Maleate?

Approved indications include: Ulcerative colitis, Rheumatoid arthritis.

When does the Filgotinib Maleate patent expire?

No public expiry year is available for Filgotinib Maleate yet; this page updates once verified.

How do I get a quote for Filgotinib Maleate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27